Arbutus Biopharma Corporation Company Profile (NASDAQ:ABUS)

Arbutus Biopharma Corporation trades on the NASDAQ under the ticker symbol "ABUS."

Arbutus Biopharma Corporation (NASDAQ:ABUS) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($0.34) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.04. The company earned $0.20 million during the quarter, compared to analysts' expectations of $7.50 million. View Arbutus Biopharma Corporation's Earnings History.

Arbutus Biopharma Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Arbutus Biopharma Corporation.

7 analysts have issued 12 month target prices for Arbutus Biopharma Corporation's stock. Their forecasts range from $5.00 to $32.00. On average, they anticipate Arbutus Biopharma Corporation's share price to reach $12.00 in the next twelve months. View Analyst Ratings for Arbutus Biopharma Corporation.

Here are some recent quotes from research analysts about Arbutus Biopharma Corporation stock:

• 1. According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (7/10/2017)
• 2. Wedbush analysts commented, "We believe ABUS remains undervalued ahead of key clinical readouts in 2017 for its HBV pipeline candidates, a mid:17 readout of Alnylam's Ph 3 patisiran study in ATTR that could lead to a significant royalties to ABUS, and the potential for additional partnerships around its attractive LNP platform." (3/22/2017)

Arbutus Biopharma Corporation saw a increase in short interest in the month of June. As of June 15th, there was short interest totalling 747,529 shares, an increase of 33.1% from the May 31st total of 561,799 shares. Based on an average daily trading volume, of 195,444 shares, the days-to-cover ratio is presently 3.8 days. Currently, 2.2% of the shares of the company are sold short.

Some companies that are related to Arbutus Biopharma Corporation include Novavax (NVAX), Adamas Pharmaceuticals (ADMS), Abeona Therapeutics (ABEO), PDL BioPharma (PDLI), Celyad SA (CYAD), Concert Pharmaceuticals (CNCE), Celldex Therapeutics (CLDX), Puretech Health PLC (PRTC), Curis (CRIS), Nabriva Therapeutics AG (NBRV), Idera Pharmaceuticals (IDRA), Advaxis (ADXS), Codexis (CDXS), Voyager Therapeutics (VYGR), Corvus Pharmaceuticals (CRVS), Organovo Holdings (ONVO), Zynerba Pharmaceuticals (ZYNE) and Horizon Discovery Group PLC (HZD).

Arbutus Biopharma Corporation's management team includes the folowing people:

• Vivek Ramaswamy, Chairman of the Board
• Mark J. Murray Ph.D., President, Chief Executive Officer, Director
• Bruce G. Cousins, Chief Financial Officer, Executive Vice President
• Elizabeth Howard, Executive Vice President, General Counsel
• Peter Lutwyche Ph.D., Chief Technology Officer
• Michael Joseph Sofia, Chief Scientific Officer
• William Thomas Symonds III, Chief Development Officer, Director
• Michael J. Abrams Ph.D., Managing Director - Non-HBV Assets
• Patrick T. Higgins, Chief Business Officer
• Daniel D. Burgess, Director

Arbutus Biopharma Corporation's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (1.59%). View Institutional Ownership Trends for Arbutus Biopharma Corporation.

Arbutus Biopharma Corporation's stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can. View Insider Buying and Selling for Arbutus Biopharma Corporation.

Shares of Arbutus Biopharma Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Arbutus Biopharma Corporation stock can currently be purchased for approximately $3.80.